An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine.

To evaluate the effectiveness of Vi polysaccharide vaccine (Vi vaccine) in preventing typhoid fever, an analysis was done of an outbreak of typhoid fever among students attending a middle school in the People's Republic of China, where Vi vaccine is licensed for use. Vi vaccine effectiveness was analyzed by using Cox proportional hazards modeling to account for the time-dependent nature of vaccination and illness status during the outbreak. Among 1260 students who had been immunized before the outbreak, receipt of Vi vaccine was associated with 73% (95% confidence interval [CI], 32%-89%) protection. Among the additional 441 students immunized during the outbreak, receipt of Vi vaccine was associated with 71% (95% CI, -9% to 92%) protection. These results provide the first evidence about the effectiveness of Vi vaccine when deployed routinely in a typhoid-endemic area and support the use of Vi vaccine as a public health tool to control typhoid fever.

[1]  R. Tauxe,et al.  Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise. , 2000, JAMA.

[2]  J. Wain,et al.  Epidemic Typhoid in Vietnam: Molecular Typing of Multiple-Antibiotic-Resistant Salmonella enterica Serotype Typhi from Four Outbreaks , 2000, Journal of Clinical Microbiology.

[3]  D. D. Trach,et al.  Safety and Immunogenicity of Vi Conjugate Vaccines for Typhoid Fever in Adults, Teenagers, and 2- to 4-Year-Old Children in Vietnam , 1999, Infection and Immunity.

[4]  Z. Bhutta,et al.  Rapid serologic diagnosis of pediatric typhoid fever in an endemic area: a prospective comparative evaluation of two dot-enzyme immunoassays and the Widal test. , 1999, The American journal of tropical medicine and hygiene.

[5]  J. Wain,et al.  Value of a Single-Tube Widal Test in Diagnosis of Typhoid Fever in Vietnam , 1999, Journal of Clinical Microbiology.

[6]  B. Singh,et al.  Typhoid fever in children aged less than 5 years , 1999, The Lancet.

[7]  H. Vohra,et al.  Protective Efficacy and Immunogenicity of Vi‐Porin Conjugate against Salmonella typhi , 1999, Microbiology and immunology.

[8]  E. Threlfall,et al.  Ciprofloxacin-resistant Salmonella typhi and treatment failure , 1999, The Lancet.

[9]  S. Saha,et al.  A highly ceftriaxone-resistant Salmonella typhi in Bangladesh. , 1999, The Pediatric infectious disease journal.

[10]  N. White,et al.  A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group. , 1999, The Pediatric infectious disease journal.

[11]  J. Wain,et al.  Typhoid fever--important issues still remain. , 1998, Trends in microbiology.

[12]  T. Cheasty,et al.  Resistance to ciprofloxacin in pathogenic Enterobacteriaceae in England and Wales in 1996. , 1997, Journal of clinical pathology.

[13]  J. Shi,et al.  [Efficacy and side effects following immunization with Salmonella typhi Vi capsular polysaccharide vaccine]. , 1997, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[14]  J. Robbins,et al.  Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. , 1996, Vaccine.

[15]  Z. Bhutta,et al.  Therapy of multidrug-resistant typhoid fever with oral cefixime vs. intravenous ceftriaxone. , 1994, The Pediatric infectious disease journal.

[16]  J. Shiloach,et al.  Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines , 1994, Infection and immunity.

[17]  N. Cn,et al.  Multidrug resistant Salmonella typhi in Bangalore, south India. , 1994 .

[18]  S. Oppenheimer,et al.  Usefulness of the Widal test in diagnosing childhood typhoid fever in endemic areas , 1993, Journal of paediatrics and child health.

[19]  K. Goh,et al.  Epidemiology and control of an outbreak of typhoid in a psychiatric institution , 1992, Epidemiology and Infection.

[20]  S. Hoffman,et al.  Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine , 1991, The Lancet.

[21]  X H Liu,et al.  The Cox proportional hazards model with change point: an epidemiologic application. , 1990, Biometrics.

[22]  M. Levine,et al.  Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. , 1990, Vaccine.

[23]  M. Levine,et al.  Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. , 1989, The Journal of infectious diseases.

[24]  R. Schneerson,et al.  PROTECTIVE ACTIVITY OF VI CAPSULAR POLYSACCHARIDE VACCINE AGAINST TYPHOID FEVER , 1987, The Lancet.

[25]  R. Thapa,et al.  Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. , 1987, The New England journal of medicine.

[26]  P. Echeverria,et al.  Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine. , 1987, Reviews of infectious diseases.

[27]  Zheng Qs.  The antimicrobial resistance of S. typhi and an outbreak of typhoid fever , 1987 .

[28]  R. Black,et al.  LARGE-SCALE FIELD TRIAL OF TY21A LIVE ORAL TYPHOID VACCINE IN ENTERIC-COATED CAPSULE FORMULATION , 1987, The Lancet.

[29]  J M Robins,et al.  Estimation of a common effect parameter from sparse follow-up data. , 1985, Biometrics.

[30]  S. Puthucheary,et al.  Significance and value of the Widal test in the diagnosis of typhoid fever in an endemic area. , 1983, Journal of clinical pathology.

[31]  A. Shehabi.  The value of a single Widal test in the diagnosis of acute typhoid fever. , 1981, Tropical and geographical medicine.

[32]  E. Threlfall,et al.  Chloramphenicol-resistant S typhimurium , 1979, Veterinary Record.

[33]  A. González-Cortés,et al.  Water-borne transmission of chloramphenicol-resistant Salmonella typhi in Mexico. , 1973, Lancet.

[34]  S. Zhang,et al.  Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. , 2001, Bulletin of the World Health Organization.

[35]  E J Threlfall,et al.  Molecular epidemiology of antibiotic resistance genes in multiresistant epidemic Salmonella typhimurium DT 104. , 1998, Microbial drug resistance.

[36]  E. Threlfall,et al.  Multidrug-resistant Salmonella typhi: a worldwide epidemic. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  M. Levine,et al.  Vaccination against typhoid fever: present status. , 1994, Bulletin of the World Health Organization.

[38]  B. Walia,et al.  Multi-drug-resistant Salmonella typhi--a need for therapeutic reappraisal. , 1992, Annals of tropical paediatrics.